clinical practice
clinical practice
‘ First-in-class ’
Experts develop rapid test for potentially fatal pregnancy complication .
By Elise Hartevelt
Australian researchers have developed a new test to enable the early diagnosis of preeclampsia , a potentially fatal pregnancy condition and one of the leading causes of maternal death worldwide .
Experts from the University of Technology Sydney created the 15-minute test based on the discovery of two new biomarkers , FKBPL and CD44 .
Preeclampsia , the most dangerous form of high blood pressure during pregnancy , can lead to severe organ damage and affects roughly 5 to 8 per cent of pregnancies in Australia .
Lead researcher Associate Professor Lana McClements said the test will enable clinicians to make a faster and more accurate diagnosis .
“ We believe this test has the potential to revolutionise the way preeclampsia is diagnosed and managed ,” Professor McClements told Nursing Review .
Preeclampsia most commonly develops during the later stages of pregnancy and often occurs in first-time pregnancies . Direct causes of the condition are unclear , but recent studies indicate that genetics may account for up to 55 per cent of cases .
20 | nursingreview . com . au
Early indicators of preeclampsia include a sudden rise in blood pressure and the appearance of proteins , called proteinuria , in the urine .
Other symptoms include dizziness , headaches , nausea , abdominal pain , and swelling around the ankles , hands and feet .
If left untreated preeclampsia can lead to serious complications such as seizures , kidney and liver failure , blood clots , or death .
“ A reliable , fast test with a clinical assessment whilst the patient is still at the doctor ’ s office will increase the likelihood someone receives care at a critical time ,” Professor McClements said .
“ The novel biomarkers also show potential as drug and cell therapy targets of emerging treatments for preeclampsia , offering hope for a future cure to this terrible disorder .”
The 15-minute rapid test is a strip-based lateral flow test that involves adding a plasma sample extracted from blood to quantify concentrations of the two biomarkers .
`Professor McClements said the team was inspired by the Covid-19 rapid test and used a similar approach in the preeclampsia design .
“ This is the first-in-class rapid test for preeclampsia using this platform ,” Professor McClements said .
“ There are other points of care tests for preeclampsia ; however , these are based on different platforms and biomarkers , and less sensitive .”
The current method for diagnosing preeclampsia includes measuring blood pressure , testing for protein in the urine , and assessing other clinical signs and symptoms .
Professor McClements said the condition could express itself differently for every pregnancy , making diagnosing challenging .
Someone might not experience any symptoms until it becomes very dangerous , she said .
“ Diagnosis is often delayed , which has potential negative consequences for the mother and her baby .
“ Timely diagnosis is key in preventing complications and fatal outcomes .”
She said the rapid test could prove especially useful in rural and remote parts of Australia and developing countries with poor access to prenatal care .
While most mothers giving birth in Australia ’ s remote areas had healthy pregnancies , they were at a higher risk of adverse outcomes when complications did occur .
Professor McClements said she hoped the rapid tests would reach the market within two to five years .
The team is looking for industry partners to make it available to clinicians and healthcare professionals .
“ We hope the test has great potential to make a real difference for both mothers and babies ,” she said . ■